Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: EN Brussels
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

ThromboGenics NV

+ Add to Watchlist

THR:BB

7.6500 EUR 0.1000 1.32%

As of 07:20:30 ET on 03/03/2015.

Snapshot for ThromboGenics NV (THR)

Open: 7.7000 Day's Range: 7.6500 - 7.9300 Volume: 78,853
Previous Close: 7.5500 52wk Range: 6.0200 - 24.0000 1-Yr Rtn: -61.53%

Stock Chart for THR

No chart data available.
  • THR:BB 7.6700
  • 1D
  • 1M
  • 1Y
7.5500
Interactive THR Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for THR

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. BEL20 -
Earnings Per Share (EUR) (ttm) -1.4500
Est. EPS (EUR) (12/2014) -1.2750
Est. PEG Ratio -
Market Cap (M EUR) 278.43
Shares Outstanding (M) 36.09
30 Day Average Volume 74,278
Price/Book (mrq) 1.1823
Price/Sale (ttm) 16.1241
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 03/12/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for THR

  • Revenue
  • Net Income (M/EUR)
  • Profit Margin (%)

Company Profile & Key Executives for THR

ThromboGenics NV is a biopharmaceutical company focused on the development of therapeutics for conditions related to the vascular system. The Company is focused on developing medicines to treat visual disorders, cardiovascular diseases, and cancer, conditions which result from abnormalities to the vascular system.

Gustaaf Van Reet "Staf"ChairmanPatrik De HaesCEO/Executive Director
Dominique VanfleterenChief Financial OfficerKoen KasChief Scientific Officer
More Company Profile & Key Executives for THR

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil